Ads
related to: von willebrand disease explained- On-Demand Information
This treatment is indicated for use
as an on-demand therapy for VWD.
- Dosing Guidelines
Find dosing guidelines
for 3 indications.
- Treatment Administration
Learn about treatment storage,
reconstitution, and administration.
- Surgery Information
See how this treatment is used to
prepare for surgeries.
- On-Demand Information
Search results
Results from the WOW.Com Content Network
Von Willebrand disease (VWD) is the most common hereditary blood-clotting disorder in humans. An acquired form can sometimes result from other medical conditions. [1] It arises from a deficiency in the quality or quantity of von Willebrand factor (VWF), a multimeric protein that is required for platelet adhesion. It is known to affect several ...
Von Willebrand factor (VWF) (German: [fɔn ˈvɪləbʁant]) is a blood glycoprotein that promotes primary hemostasis, specifically, platelet adhesion.It is deficient and/or defective in von Willebrand disease and is involved in many other diseases, including thrombotic thrombocytopenic purpura, Heyde's syndrome, and possibly hemolytic–uremic syndrome. [5]
The important role of depletion of von Willebrand factor in aortic stenosis was first proposed in 1992 by Warkentin et al. [7] They noted a known association between aortic stenosis (in addition to other cardiac diseases) and acquired von Willebrand's disease type IIA, [20] which is corrected by surgical replacement of the aortic valve. They ...
Von Willebrand Disease (vWD) is an inherited blood clotting disorder, similar (but different to) hemophilia. It is known to affect dogs, humans, and many other species, but it’s not contagious ...
Von Willebrand disease (which behaves more like a platelet disorder except in severe cases), is the most common hereditary bleeding disorder and is characterized as being inherited autosomal recessive or dominant. In this disease, there is a defect in von Willebrand factor (vWF), which mediates the binding of glycoprotein Ib (GPIb) to collagen.
It is similar to the ristocetin cofactor assay but has the added benefit in that it helps in the diagnosis of type 2B/pseudo von Willebrand disease (vWD) and Bernard–Soulier syndrome because it uses patient's live endogenous platelets, whereas ristocetin cofactor assay tests the function of only the vWF and not the platelets. Ristocetin ...
Von Willebrand described this disorder in 1926, distinguishing it from hemophilia. The disorder was named after him, becoming known as von Willebrand disease. The cause of the disease was later discovered to be a deficiency of a protein, now known as von Willebrand factor, that enables hemostasis.
Type III von Willebrand Disease is a severe bleeding disorder, like severe hemophilia type A or B. VWF acts in primary hemostasis to recruit platelets at a site of injury, and is also important in secondary hemostasis, acting as a chaperone for coagulation factor VIII (FVIII). [20]
Ads
related to: von willebrand disease explained